The use of PCa as a model for TNP development is especially timely as hypoxia crosses the intersection of androgen receptor (AR) signaling heavens (hormone therapy resistance) leading to progression to castration‐resistant PCa (CRPC) and as the Prostate‐Specific Membrane Antigen (PSMA) is greatly overexpressed and is a validated target for custom imaging and treatment. Here, FOLH1 is linked to posterior cortical atrophy.